Neural Board is led by Tatiana Pilipenko, PhD, a biostatistician and medical data scientist. We help health companies, research teams and clinics check whether their data, models and AI claims hold up.
"The FDA authorized 258 AI medical devices in 2025, most through pathways that do not require new clinical trials." The report adds: "…with only 2.4% of devices with clinical studies supported by randomized trial data." (Stanford HAI, AI Index Report 2026)

We check your analysis plan and results from outside your team. We rebuild the main analyses from your plan and your pseudonymized data, then send a signed memo with a clear verdict. Fixed price.

We review the published studies behind a health product or claim and write a short report that separates what the evidence confirms from what it does not.

We help you choose, test and validate AI tools for clinical and research use. We do not build or sell AI tools, so our advice has no stake in what you pick.


1. You write to us and describe the question.
2. We reply with a written scope, price and delivery date.
3. We do the work and send the report or memo.

Have an analysis, a model or a claim that needs a second pair of eyes? Describe it in a few lines.
Plain-language articles on AI in medicine, with the studies behind them.
Write to us about your project.